European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Novartis Pharma GmbH, Vienna, Austria

Watch
Novartis Pharma GmbH

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier is a comprehensive company details as a PDF and publications in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Complete Dossier
Entire company details along with publications bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €/month

Learn more
Learn more
View plans
Risk report
Novartis Pharma GmbH
Risk Level Evaluation Source
Sanctioned (?)

Name

Novartis Pharma GmbH
Sandoz GmbH

Identification

Fb
Firmenbuch 041622i
Lei
529900OVNGQLN18QMN97
EUID
ATBRA.041622-000

Address

Jakov-Lind-Straße 5, Top 3.05, 1020 Wien, Austria

Financial performance

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information · Proxy policies Premium
Premium
2Managing Director
2Authorized signatory (ppa)
Upgrade to unlock all features

Premium plans starting from €/month

Learn more View plans
Learn more View plans
Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
2 known active shareholders
Upgrade to unlock all features

Premium plans starting from €/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Earnings CAGR
Revenue
Revenue CAGR
Return on sales
Equity
Equity ratio
Return on equity
Employee number
Revenue per employee
Taxes
Tax ratio
Receivables
Liabilities
Cost of materials
Wages and salaries
Average salaries per employee
Pension provisions
Real estate
Patents
Upgrade to unlock all features

Premium plans starting from €/month

Learn more View plans
Learn more View plans
Financial Statements Interactive sheets with CSV/Excel download Premium
Premium
Balance
from 2023 to 2024
Profit & Loss
from 2023 to 2024
Upgrade to unlock all features

Premium plans starting from €/month

Learn more View plans
Learn more View plans

Publications

15 Oct 2025
No longer Authorized signatory (ppa): Ch. Miksch-Aichenegg
1 Oct 2025
Authorized signatory (ppa): Hanno Gerritsmann
13 Sept 2025
Annual report for the year ending 31/12/2024 · Balance sheet for 31/12/2024 · Earnings statement for 31/12/2024
28 Jun 2025
Managing Director: Sergey Kerdod · Authorized signatory (ppa): Ch. Miksch-Aichenegg · No longer Managing Director: Swen Harke, Ch. Miksch-Aichenegg
17 May 2025
Managing Director: Catherine Emond
19 Mar 2025
Managing Director: Swen Harke, Ch. Miksch-Aichenegg · No longer Managing Director: Wilhelm Golubich · No longer Authorized signatory (ppa): Ch. Miksch-Aichenegg
12 Feb 2025
Patent: Pharmaceutical composition containing glycopyrrolate and a beta2-adrenoceptor antagonist
16 Nov 2024
Annual report for the year ending 31/12/2023 · Balance sheet for 31/12/2023
4 Sept 2024
No longer Authorized signatory (ppa) (1)
21 Aug 2024
No longer Managing Director: Kuntal Baveja
28 Sept 2023
Annual report for the year ending 31/12/2022
12 Jul 2023
Shareholder: Novartis Holding GmbH · No longer Shareholder: Novartis Austria GmbH · Capital: €1,091,000
4 Apr 2023
No longer Authorized signatory (ppa) (1)
2 Mar 2023
Managing Director: Kuntal Baveja · Authorized signatory (ppa): Martina Grad-Brugger · No longer Managing Director: Martina Grad-Brugger
2 Dec 2022
No longer Authorized signatory (ppa) (1)
9 Nov 2022
Annual report for the year ending 31/12/2021
1 Oct 2022
No longer Authorized signatory (ppa) (1)
14 Sept 2022
Managing Director: Martina Grad-Brugger · No longer Authorized signatory (ppa): Martina Grad-Brugger
9 Aug 2022
Managing Director: Wilhelm Golubich · No longer Managing Director (3) · No longer Authorized signatory (ppa) (1)
24 Jun 2022
Managing Director: Guro Bjontegaard · Authorized signatory (ppa) (1) · No longer Authorized signatory (ppa) (1)
25 Mar 2022
Authorized signatory (ppa) (1) · No longer Authorized signatory (ppa) (1)
23 Nov 2021
Annual report for the year ending 31/12/2020
1 Sept 2021
No longer Authorized signatory (ppa) (1)
28 Aug 2021
Authorized signatory (ppa) (1)
3 Jul 2021
No longer Authorized signatory (ppa) (1)
26 May 2021
No longer Authorized signatory (ppa): Swen Harke
22 May 2021
Authorized signatory (ppa) (2) · No longer Authorized signatory (ppa) (1)
17 Feb 2021
Authorized signatory (ppa) (1) · No longer Authorized signatory (ppa) (1)
10 Dec 2020
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019
25 Sept 2020
Managing Director: Shirley Gil Parrado · No longer Managing Director: Chinmay Bhatt · Authorized signatory (ppa) (1)
19 Sept 2020
Address
10 Jun 2020
No longer Authorized signatory (ppa) (1)
7 Mar 2020
Authorized signatory (ppa) (1)
23 Oct 2019
No longer Authorized signatory (ppa) (3) · Authorized signatory (ppa) (2)
18 Sept 2019
Annual report for the year ending 31/12/2018
24 Aug 2019
Authorized signatory (ppa) (1)
8 Mar 2019
Authorized signatory (ppa) (2) · No longer Authorized signatory (ppa) (1)
2 Feb 2019
No longer Authorized signatory (ppa) (1)
20 Oct 2018
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017
29 Sept 2018
Resolution of the Annual General Meeting of 27.08.2018 Amendment of the Articles of Association in points III., VI …
13 Jul 2018
No longer Authorized signatory (ppa) (2) · Authorized signatory (ppa) (1)
14 Apr 2018
Managing Director: Aljoscha Stroh · No longer Managing Director: Andrea Rizzi
11 Apr 2018
Patent: IL-17 Antagonistic Antibodies
22 Dec 2017
No longer Authorized signatory (ppa) (1)
8 Nov 2017
Patent: Method for Preparing Silicone Hydrogels
3 Oct 2017
Annual report for the year ending 31/12/2016 (only announcement)
30 Sept 2017
Authorized signatory (ppa) (1)
27 Sept 2017
Authorized signatory (ppa) (1) · No longer Authorized signatory (ppa) (1)
23 Aug 2017
Patent: Crystalline Forms of 4-Methyl-N-[3-(4-Methyl-Imidazol-1-yl)-5-Trifluoromethyl-Phenyl]-3-(4-Pyridin-3-yl-Pyrimidin-2-Ylamino)-Benzamide Sulfate and its Amorphous Form
19 Jul 2017
Patent: Production of 2-Amino-2-[2-(4-Alkyl-Phenyl)Ethyl]Propane-1,3-Diols
4 Jul 2017
Managing Director: Chinmay Bhatt · No longer Managing Director: Georgios I. Zarkalis
16 May 2017
Authorized signatory (ppa) (2)
10 Feb 2017
Authorized signatory (ppa) (1)
9 Feb 2017
Authorized signatory (ppa) (2) · No longer Authorized signatory (ppa) (1)
29 Sept 2016
Authorized signatory (ppa) (2)
15 Sept 2016
Annual report for the year ending 31/12/2015 (only announcement)
Year 2016 in Epobase
5 European patent filings: Disease-Associated Protein …
14 Jul 2016
No longer Authorized signatory (ppa) (1)
5 Mar 2016
Authorized signatory (ppa) (1)
11 Nov 2015
No longer Authorized signatory (ppa) (1)
Year 2015 in Epobase
5 European patent filings: Manufacture Process of N-Substituted Salicylamides …
29 Aug 2015
Annual report for the year ending 31/12/2014 (only announcement)
13 Jun 2015
No longer Authorized signatory (ppa) (3) · Authorized signatory (ppa) (1)
15 Apr 2015
Managing Director: Andrea Rizzi · No longer Managing Director (1)
15 Jan 2015
Authorized signatory (ppa) (1)
Year 2014 in Epobase
18 European patent filings: Stabilized Insulin-Like Growth Factor Polypeptides …
10 Dec 2014
Authorized signatory (ppa) (1) · No longer Authorized signatory (ppa) (1)
1 Nov 2014
No longer Authorized signatory (ppa) (1)
9 Aug 2014
Annual report for the year ending 31/12/2013 (only announcement)
27 May 2014
No longer Authorized signatory (ppa) (1)
30 Jan 2014
Authorized signatory (ppa) (1)
Year 2013 in Epobase
19 European patent filings: Use of Fluorinated Triazoles for Treating Affective or Attention Disorders …
15 Oct 2013
Authorized signatory (ppa) (1) · No longer Managing Director (1)
10 Aug 2013
Managing Director (1) · Authorized signatory (ppa) (2) · No longer Authorized signatory (ppa) (1)
10 Aug 2013
No longer Authorized signatory (ppa) (2) · Authorized signatory (ppa) (1)
3 Aug 2013
Annual report for the year ending 31/12/2012 (only announcement)
14 May 2013
No longer Authorized signatory (ppa) (2) · Authorized signatory (ppa) (1)
21 Feb 2013
No longer Authorized signatory (ppa) (2) · Managing Director (2)
13 Dec 2012
Authorized signatory (ppa) (2)
Year 2012 in Epobase
26 European patent filings: Pyridylacetylenes for USE AS Radiotracers and Imaging Agents …
21 Nov 2012
No longer Authorized signatory (ppa) (1)
4 Aug 2012
Annual report for the year ending 31/12/2011 (only announcement)
5 Jun 2012
No longer Authorized signatory (ppa) (1)
24 Mar 2012
Authorized signatory (ppa) (3) · No longer Authorized signatory (ppa) (1)
Year 2011 in Epobase
30 European patent filings: Modified Amino Acid 5-Cnac for the Inhibition of Platelet Aggregation …
6 Aug 2011
Annual report for the year ending 31/12/2010 (only announcement)
15 Apr 2011
Patent: Stabilisierung von Macrolide
26 Jan 2011
Authorized signatory (ppa) (1) · No longer Authorized signatory (ppa) (1)
Year 2010 in Epobase
40 European patent filings: Depot Formulations of Iloperidone and a Star Polymer …
6 Nov 2010
Annual report for the year ending 31/12/2009 (only announcement)
15 Jun 2010
Authorized signatory (ppa) (2) · No longer Authorized signatory (ppa) (1)
15 Jan 2010
Address
5 Jan 2010
Authorized signatory (ppa) (1)
Year 2009 in Epobase
74 European patent filings: Ophthalmic Composition Comprising an Ascomycin …
7 Nov 2009
Generalversammlungsbeschluss vom 21.09.2009 Änderung des Gesellschaftsvertrages in den Punkten II., VII. und VIII
5 Nov 2009
Seat: Vienna, Austria
30 Oct 2009
Resolution of the Annual General Meeting of 21.09.2009 division to include a part of the assets of the Sandoz GmbH (FN …
13 Oct 2009
Seat: Vienna, Austria
16 Sept 2009
Annual report for the year ending 31/12/2008 (only announcement)
Year 2008 in Epobase
63 European patent filings: Pharmaceutical Composition Comprising 5-Methyl-2-2'-(Chloro-6'-Fluoroanilino)Phenylacetic Acid …
10 Oct 2008
Annual report for the year ending 31/12/2007 (only announcement)
7 Oct 2008
No longer Authorized signatory (ppa) (1)
23 Jul 2008
No longer Authorized signatory (ppa) (2)
15 Jan 2008
Authorized signatory (ppa) (1) · No longer Authorized signatory (ppa) (1)
Year 2007 in Epobase
121 European patent filings: Combinations Comprising a Selective Cyclooxygenase-2 Inhibitor …
21 Aug 2007
Annual report for the year ending 31/12/2006 (only announcement)
17 Jan 2007
Patent: Stabilisierung von Macrolide
Year 2006 in Epobase
182 European patent filings: Benzamidoacetonitrile Derivatives and Their USE AS Antiparasitics …
22 Sept 2006
Annual report for the year ending 31/12/2005 (only announcement)
9 Aug 2006
Shareholder: Novartis AG, Novartis Austria GmbH · Capital: €1,091,000
7 Jun 2006
Patent: Brillenlinse mit Optimalem Power-Profil
8 Mar 2006
Authorized signatory (ppa) (1) · No longer Authorized signatory (ppa) (1)
Year 2005 in Epobase
179 European patent filings: 2-Amino-Propanol Derivatives …
7 Sept 2005
Authorized signatory (ppa) (2) · No longer Authorized signatory (ppa) (1)
23 Jun 2005
Annual report for the year ending 31/12/2004 (only announcement)
15 Jan 2005
Managing Director (1) · No longer Managing Director (1)
16 Sept 2004
No longer Authorized signatory (ppa) (1)
1 Sept 2004
Annual report for the year ending 31/12/2003 (only announcement)
17 Apr 2004
No longer Authorized signatory (ppa) (2)
3 Jul 2003
Annual report for the year ending 31/12/2002 (only announcement)
11 Oct 2002
Authorized signatory (ppa) (1) · Merger: Novartis-Erfindungen Verwaltungsgesellschaft mbH
21 Aug 2002
Annual report for the year ending 31/12/2001 (only announcement)
7 Mar 2002
Authorized signatory (ppa) (1)
27 Jul 2001
Shareholder: Novartis AG · Capital: €1,091,000
12 Jul 2001
Annual report for the year ending 31/12/2000 (only announcement)
12 Jul 2001
Managing Director (1) · No longer Managing Director (1) · No longer Authorized signatory (ppa) (1)
1 Mar 2001
Resolution of the Annual General Meeting of 21.02.2001 demerger to absorb a part of the assets of the CIBA Vision GmbH  …
3 Oct 2000
Authorized signatory (ppa) (1) · No longer Authorized signatory (ppa) (1)
1 Jul 2000
Annual report for the year ending 31/12/1999 (only announcement)
25 Sept 1999
No longer Authorized signatory (ppa) (2)
25 Aug 1999
Annual report for the year ending 31/12/1998 (only announcement)
19 Nov 1998
Managing Director (1) · No longer Managing Director (1)
16 Sept 1998
Merger agreement dated 01.09.1998 Resolution of the General Assembly of 01.09.1998 of the SANABO Wien GmbH (FN 127395 …
15 Sept 1998
Annual report for the year ending 31/12/1997 (only announcement)
17 Jul 1998
No longer Authorized signatory (ppa) (1)
18 Feb 1998
No longer Authorized signatory (ppa) (2) · Authorized signatory (ppa) (2)
6 Sept 1997
Annual report for the year ending 31/12/1996 (only announcement)
29 May 1997
No longer Authorized signatory (ppa) (1)
22 Mar 1997
Firmenbuch - Vollzug - Republik Österreich vertreten durch das BMJ
19 Mar 1997
No longer Managing Director (1) · Shareholder: Novartis AG · No longer Shareholder: SANDOZ AG, Basel, Schweiz · Capital: 15M ATS · Name: Novartis Pharma GmbH · Proxy policy
5 Feb 1997 as Sandoz GmbH
Authorized signatory (ppa) (2)
14 Jan 1997 as Sandoz GmbH
Managing Director (1) · No longer Authorized signatory (ppa) (1)
21 May 1996 as Sandoz GmbH
Annual report for the year ending 31/12/1995 (only announcement)
30 Jan 1996 as Sandoz GmbH
Authorized signatory (ppa) (2)
15 Dec 1995 as Sandoz GmbH
Shareholder: SANDOZ AG, Basel, Schweiz · Capital: 15M ATS
12 Dec 1995 as Sandoz GmbH
Annual report for the year ending 31/12/1994 (only announcement)
31 Oct 1995 as Sandoz GmbH
No longer Authorized signatory (ppa) (11) · No longer Managing Director (1)
26 Aug 1995 as Sandoz GmbH
Resolution of the Annual General Meeting of 17.08.1995 Capital reduction by ATS 5,000,000 to ATS 15,000,000 intended
27 Jul 1995 as Sandoz GmbH
Contribution agreement of 23.06.1995 Introduction of the chemicals sub-plant into the Sandoz Chemikalien GmbH, Vienna ( …
24 Mar 1995 as Sandoz GmbH
Annual report for the year ending 31/12/1993 (only announcement)
3 Feb 1995 as Sandoz GmbH
Authorized signatory (ppa) (2)
26 Jul 1994 as Sandoz GmbH
No longer Authorized signatory (ppa) (3) · Authorized signatory (ppa) (2)
26 Apr 1994 as Sandoz GmbH
Annual report for the year ending 31/12/1992 (only announcement)
4 Feb 1994 as Sandoz GmbH
Authorized signatory (ppa) (3) · No longer Authorized signatory (ppa) (1)
4 Aug 1993 as Sandoz GmbH
Reg­is­tra­tion: 04/08/1993 · ppa (18) · MD (3) · SH: SANDOZ AG, Basel, Schweiz · Address · Deadline for annual balance: 31.12. · Capital: 20M ATS · Seat: Vienna, Austria …
There are no publications matching your search.

Mentions

30 Dec 2021 in Ler
Direct parent
30 Dec 2021 in Ler
Ultimate parent
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.